Related to BMS, Simcere to Co-Develop Early-Stage Cardiovascular Disease Candidate

• PPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• BMS Pays $10M to Tap into Tranzyme’s Macrocyclic Compound Discovery Expertise
  
• Cambridge University and Chi-Med to Study Angiogenesis Effects of Chinese Medicinal Plants
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• BMS Gives Up $40M in Exchange for Allergan’s Neuropathic Pain Drug
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China
  
• Recordati Signs Up Esteve as Marketing Partner for Pitavastatin in Spain
  
• ICON and Tigermed Team Up to Facilitate Access to Chinese Patient Populations
  
• Charles River to Take Over Sino-U.S. CRO WuXi in Deal Worth $1.6B
  
• PPD Opens Vaccine Clinical Research Center in Taizhou, China
  
• BMS to Use Tekmira’s SNALP Technology for Target Validation
  
• BMS Hands Co-Development Rights for Anticancer Drug Back to Exelixis along with $17M